ARCHIVES

Phase III Cyramza Trial Meets OS Primary Endpoint

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Phase III Xtandi Trial Meets Primary Endpoints Of Progression-Free and Overall Survival

November 29, 2013

Continuing Resolution Averts Shutdown; Locks in Sequestration Cuts for NIH, NCI

March 22, 2013

Trial In Metastatic Disease To Be Unblinded After Regorafenib Meets Primary Endpoint

November 25, 2011

Organ Systems Program Adds Workshops On Lung, Colorectal Cancer

January 26, 1990

High Risk Youth Targeted In Concept Ok’d By Advisors

February 8, 1991

In Brief: Clinical Education Program to Be Phased Out; Ken Endicott Retires From Grupenhoff Firm

January 31, 1986